Starling Oncology
STLN
Starling Oncology (STLN) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| BTIG | Maintained | Buy | $9.00 from $8.00 | Jul 9, 2026 |
| Lake Street | Initiated Coverage | Buy | $10.00 | Jul 6, 2026 |
| Needham | Maintained | Buy | $7.00 from $5.00 | Jun 17, 2026 |
| BTIG | Maintained | Buy | $8.00 from $7.00 | Jun 8, 2026 |
| Needham | Maintained | Buy | $5.00 | Mar 13, 2026 |
| B. Riley Securities | Maintained | Buy | $8.00 from $6.00 | Mar 13, 2026 |
| BTIG | Maintained | Buy | $7.00 | Mar 9, 2026 |
| Needham | Maintained | Buy | $5.00 | Mar 9, 2026 |
| Needham | Initiated Coverage | Buy | $5.00 | Nov 25, 2025 |
| BTIG | Maintained | Buy | $7.00 | Oct 21, 2025 |
| B. Riley Securities | Initiated Coverage | Buy | $6.00 | Jul 16, 2025 |
| Jefferies | Initiated Coverage | Buy | $2.50 | Feb 26, 2024 |
| Guggenheim | Maintained | Buy | $2.00 from $3.00 | Jun 16, 2023 |
| Guggenheim | Maintained | Neutral | $3.00 from $6.00 | Mar 20, 2023 |
Frequently asked questions
What is the latest analyst rating on STLN?
On Jul 9, 2026, BTIG maintained Starling Oncology at Buy with a price target of $9.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.